About: Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19
Creator	Mantzoros, Christos Dalamaga, Maria Karampela, Irene
Source	Elsevier; Medline; PMC
abstract	The most severe presentation of COVID-19 is characterized by a hyperinflammatory state attributed to the massive pro-inflammatory cytokine release, called “cytokine storm”. Several specific anti-inflammatory/immunosuppressive agents are being evaluated by ongoing clinical trials; however, there is currently insufficient evidence for their efficacy and safety in COVID-19 treatment. Given the role of phosphodiesterase 4 (PDE) 4 and cyclic adenosine monophosphate in the inflammatory response, we hypothesize that selective PDE4 inhibition may attenuate the cytokine storm in COVID-19, through the upstream inhibition of pro-inflammatory molecules, particularly TNF-α, and the regulation of the pro-inflammatory/anti-inflammatory balance. Conversely, other anti-cytokine agents lead to the downstream inhibition of specific targets, such as IL-1, IL-6 or TNF-α, and may not be efficient in blocking the cytokine storm, once it has been triggered. Due to their mechanism of action targeting an early stage of the inflammatory response and ameliorating lung inflammation, we believe that selective PDE4 inhibitors may represent a promising treatment option for the early phase of COVID-19 pneumonia before the cytokine storm and severe multiorgan dysfunction take place. Furthermore, PDE4 inhibitors present several advantages including an excellent safety profile; the oral route of administration; the convenient dosing; and beneficial metabolic properties. Interestingly, obesity and diabetes mellitus type 2 have been reported to be risk factors for the severity of COVID-19. Therefore, randomized clinical trials of PDE4 inhibitors are necessary to explore their potential therapeutic effect as an adjunct to supportive measures and other therapeutic regiments.
has issue date	2020-06-01(xsd:dateTime)
bibo:doi	10.1016/j.metabol.2020.154282
bibo:pmid	32497535
has license	no-cc
sha1sum (hex)	fa3fe3397d8379d85ba1bc8d5d7ae6be542183eb
schema:url	https://doi.org/10.1016/j.metabol.2020.154282
resource representing a document's title	Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19
has PubMed Central identifier	PMC7263254
has PubMed identifier	32497535
schema:publication	Metabolism
resource representing a document's body	covid:fa3fe3397d8379d85ba1bc8d5d7ae6be542183eb#body_text
is schema:about of	named entity 'cytokine storm' named entity 'Commentary' named entity 'treatment' named entity 'Abstract' named entity 'Phosphodiesterase 4 inhibitors' named entity 'upregulated' named entity 'acute lung injury' named entity 'protein kinase' named entity 'pneumonia' named entity 'Apremilast' named entity 'obesity' named entity 'PKA' named entity 'influenza' named entity 'H1N1 virus' named entity 'case report' named entity 'crisaborole' named entity 'attenuate' named entity 'dendritic' named entity 'inflammatory response' named entity 'rheumatoid arthritis' named entity 'obesity' named entity 'IL-12' named entity 'PDE4 inhibition' named entity 'inflammatory diseases' named entity 'COVID' named entity 'IL-6' named entity 'proinflammatory' named entity 'CD4+' named entity 'obesity' named entity 'monoclonal antibodies' named entity 'intracellular' named entity 'cyclic adenosine monophosphate' named entity 'pro-inflammatory cytokines' named entity 'COPD' named entity 'inflammatory response' named entity '3, 4' named entity 'IL-1' named entity '19, 20' named entity 'COVID-19' named entity 'immunosuppressive agents' named entity 'apremilast' named entity 'morbidity' named entity 'nuclear factor kB' named entity 'inflammatory bowel disease' named entity 'TNFα' named entity 'COVID' named entity 'route of administration' named entity 'weight loss' named entity 'severe respiratory failure' named entity 'Janus kinase' named entity 'COVID' named entity 'psoriatic arthritis' named entity 'cytokine storm' named entity 'epithelium' named entity 'intubation' named entity 'lung fibrosis' named entity 'signaling pathways' named entity 'macrophages' named entity 'COVID' named entity 'apremilast' named entity 'adverse effects' named entity 'immunosuppressed' named entity 'adaptive immune response' named entity 'neutrophils' named entity 'clinical presentation' named entity 'orally administered' named entity 'IL-10' named entity 'gastrointestinal' named entity 'IL-17' named entity 'enzyme' named entity 'atopic dermatitis' named entity 'IL-2' named entity 'COVID-19' named entity 'receptor antagonist' named entity 'inflammatory diseases' named entity 'lung injury' named entity 'IL-17' named entity 'body weight' named entity 'lipolysis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software